Megan Hollasch

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not statistically significant.

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases.

When added to tivozanib, nivolumab did not lead to improved clinical outcomes in metastatic renal cell carcinoma.

Disease duration, thrombotic event history, elevated WBC count, HCT levels, and VAF are key predictors of polycythemia vera progression.

Lenvatinib in combination with pembrolizumab yielded a greater clinical benefit rate compared with sunitinib in advanced clear cell renal cell carcinoma, regardless of patient biomarker subtype.

CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative tumor infiltrating lymphocytes did not serve as a biomarker of improved clinical outcomes of nivolumab plus ipilimumab in metastatic ccRCC.

Patients with ROS1-positive non–small cell lung cancer responded to the next-generation inhibitor taletrectinib with acceptable toxicity.

Lorlatinib improved progression-free survival vs crizotinib when used as a treatment in patients ALK-positive non–small cell lung cancer.

ctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.

Adjuvant pembrolizumab treatment significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

ASKB589 exhibited anti-tumor activity when used alongside capecitabine and oxaliplatin, along with sintilimab, for the treatment of gastric or gastroesophageal junction cancers.

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki showed promising antitumor activity in patients with chemotherapy-naïve, HER2-low, hormone receptor-positive metastatic breast cancer.

Survival benefits for immunotherapy doublets outweigh chemotherapy alone in advanced stage PD-L1-negative non-small cell lung cancer.

In a presentation at the 2023 International Kidney Cancer Symposium, Jaleh Fallah, MD, discussed the regulatory agency’s evaluation of data from the phase 2 LITESPARK-004 trial, which led to the approval of belzutifan.

Treatment with datopotamab deruxtecan improved progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer.

The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.

Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.

Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.

According to Shirish M. Gadgeel, MD, adagrasib demonstrated durable clinical benefit [and] there were no new safety signals.

Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.

Lasofoxifene in combination abemaciclib showed antitumor activity that was not compromised by co-occuring alterations that confer endocrine resistance.

A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression-free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.

The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.

Favorable safety and efficacy data were seen with envafolimab, lenvatinib and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.

Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.

In the phase 1b/2 DESTINY-Breast07 study, positive results were shown with trastuzumab deruxtecan, even without the addition of pertuzumab.